Publications by authors named "J J Peir"
Background: This trial investigated the efficacy and safety of salvage boron neutron capture therapy (BNCT) combined with image-guided intensity-modulated radiotherapy (IG-IMRT) for recurrent head and neck cancer after prior radiotherapy (RT).
Methods: BNCT was administered using an intravenous boronophenylalanine-fructose complex (500 mg/kg) in a single fraction; multifractionated IG-IMRT was administered 28 days after BNCT. For BNCT, the mucosa served as the dose-limiting organ.
(1) Background: A well-established Boron Neutron Capture Therapy (BNCT) facility includes many essential systems, which are the epithermal neutron beam system, on-line monitoring system (OMS), QA/QC (quality assurance or quality control) system, boron concentration (BC) measurement system, and treatment planning system (TPS). Accurate data transmission, monitoring, and deposition among these systems are of vital importance before, during, and after clinical, animal, and cell BNCT irradiation. This work developed a novel integrated platform NeuTHOR Station (NeuTHORS) for BNCT at Tsing Hua Open-pool Reactor (THOR).
View Article and Find Full Text PDFArticle Synopsis
- * Recurrent meningiomas pose treatment challenges, particularly when they occur in areas previously treated with radiation.
- * This article highlights the use of Boron Neutron Capture Therapy (BNCT) in four patients with recurrent meningiomas in Taiwan, showing promising results in tumor control and supporting its effectiveness as a salvage treatment option.
Article Synopsis
- * This study used boron neutron capture therapy (BNCT) with boric acid (BA) in a rat model of OS, demonstrating effective results when irradiation occurred shortly after BA injection.
- * The findings suggest that BA-targeted BNCT can significantly shrink OS tumors and promote bone healing, offering hope for more effective treatment options.
Brainstem tumors are heterogenous and cancerous glioma tumors arising from the midbrain, pons, and the medulla that are relatively common in children, accounting for 10% to 20% of all pediatric brain tumors. However, the prognosis of aggressive brainstem gliomas remains extremely poor despite aggressive treatment with chemotherapy and radiotherapy. That means there are many life-threatening patients who have exhausted all available treatment options and are beginning to face end-of-life stage.
View Article and Find Full Text PDF